Sponsored by Legends Media*

TODAY’S TOP ALERT! 

NYSE: KNW

We have been on an absolute heater with new stock ideas lately!

Recent alerts have hit 11%, 26%, and even over 200% shortly after I mentioned them to you.

I am hoping to add another big one to the “winner’s circle” soon.

My “tactical idea” of the day is Know Labs, Inc. (KNW).

If you check out the stock’s chart, you’ll see it has been testing the upper end of the current resistance levels for several days now…

Just trading back to the previous resistance @ $.33 would be over a 30% move from the current price.

On the downside, keep a close eye on the $.20 level which has acted as support several times in the last few weeks.

As I’ll explain, this company has a lot going for it, and the right announcement could send its stock soaring…

This pioneering company says it is “committed to making a difference in the lives of millions of people around the world by developing convenient, affordable, non-invasive medical diagnostics solutions, starting with blood glucose monitoring.”

This is a trade idea that is personal to me. I think this company could truly revolutionize care for diabetes — a disease that’s near to my heart since my mother died mainly of the disease 10 years ago. 

I'm glad to support any company dedicated to saving or extending the lives of people with diabetes, but KNW has the potential to change the game truly.

As you probably know, diabetes is a chronic disease that affects nearly two billion people around the world…

It occurs when either the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces.

It’s critical for diabetics to monitor their blood sugar so they can effectively manage their condition.

For a long time, this required “glucometers” — devices that determined blood sugar based on small blood samples. This meant repeated, painful finger pricks that had obvious drawbacks.

In the mid-2000s, though, devices called Continuous Glucose Monitors (CGMs) emerged, offering continuous, real-time glucose data via a sensor inserted under the skin.

These devices were a big improvement, but they:

• Require an invasive microneedle

• Are expensive ($2,500 - $5,000)

• Have inconsistent accuracy

• Must be worn continuously

• Need a new sensor every 10-14 days

• Have a high volume of plastic disposables

KNW is trying to solve all of these problems by developing the world’s first FDA-cleared wearable and non-invasive CGM.

After several early iterations, in February this year, the company revealed KnowU™, a device that uses a proprietary sensor to measure blood glucose without ever breaking the skin.

Without getting into the weeds of the science, the device projects radio frequency into human tissue and measures voltage response as it returns back to the sensor.

KnowU takes advantage of the distinct characteristics of glucose to store certain energy  — as well as proprietary machine learning algorithms — to determine blood glucose levels.

(For more on the technical details on KnowU, see this page and this video.)

Compared to old-school CGMs, the company says the device:

• Doesn’t need to be worn continuously (it attaches via either strap or adhesive)

• Requires no disposables

• Should be 3x-5x less expensive

• Should last for years (it has a rechargeable battery)

• Determines blood glucose from the full tissue stack instead of measuring only “interstitial fluid as a proxy for blood glucose” (KNW says this is its biggest differentiator.)

Like other CGMs, KnowU allows wearers to monitor their blood glucose in real time on a companion app that the company completed with “a world class tier one app developer for major medical device companies.”

Right now, KnowU is going through clinical testing and refinement on its path to FDA submission for clearance…

Still, KNW says the device has achieved “medical grade accuracy [as] validated by multiple peer-reviewed publications.”

In March, the KNW revealed the results of a clinical research study that found the company’s proprietary sensor — incorporated in KnowU — had “an overall Mean Absolute Relative Difference (MARD) of 11.1%” compared to a measure of glucose in venous blood.

The co-investor and author of the study was Dr. Virend K. Somers of the Mayo Clinic.

KNW board member and former chair of the American Diabetes Association, Larry Ellingson, said, “Achieving this level of accuracy in the first study using a blood reference device is truly remarkable.”

In July, KNW announced the publication of its peer-reviewed study in the prestigious Diabetes Technology & Therapeutics Journal…

The results indicated that KNW’s sensor “correctly classified an individual’s glycemic status as hyperglycemic, normoglycemic, or hypoglycemic with 93.37% accuracy compared to venous blood glucose.”

The company has a massive portfolio of intellectual property, including 75 granted patents, 204 pending ones, and 53 in-process.

As a result, KNW says it is “the leading worldwide IP holder in non-invasive blood glucose monitoring” and that it “has created a defensible moat surrounding its technology.”

And that technology could be applied well beyond glucose monitoring…

While KNW is initially focused on developing its non-invasive CGM device, it believes its proprietary technology can be used to determine many other substances in the body, including alcohol, metabolized drugs, ketones, and more.

As a result, the company has multiple “shots on goal”...

In October, it revealed a strategic partnership “to embed the Know Labs sensor technology in automobile steering wheels.”

In preliminary tests in a lab setting, the company found its proprietary sensor could “non-invasively determine blood alcohol levels.”

“[I]n an automobile steering wheel [this] could prohibit an impaired individual from driving.”

In May, the company announced its “Skunkworks” Program to “focus on identifying new applications of Know Labs’ extensive intellectual property (IP) portfolio” and licensing them.

Last month, KNW indicated it had included a “going concern” paragraph in its latest 10-K filing.

In a separate press release, the company said it “believes that it has enough available cash and flexibility with its operating expenses to operate through February 28, 2025” and that it expects “to raise additional funds through the issuance of equity, preferred stock and convertible debentures.”

Three days later, it issued this press release which is worth reading in its entirety…

In brief, the company pointed out — and I agree — that it has a tremendous amount going for it and that “[m]anagement feels confident in its ability to access capital and continue operations as they execute the Company’s plans and strategic initiatives.”

Critically, the press release noted that “We are under NDA with several major companies to develop strategic joint-venture partnerships around clinical collaboration, technology, and product development.”

As you do your own research on this potentially game-changing company, be sure to review this November 2024 investor presentation and the company’s very accessible website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: KNW is out to change the standard of care for a disease affecting nearly 2 billion people, and its technology has been proving itself in spades…

Its stock had a 12% afternoon rally yesterday, and has flirted with another 12% in the pre-market already.

Don’t lose sight of KNW — it’s a must-watch today!

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Legends Media for advertising Know Labs, Inc for a one day marketing program on December 12, 2024. This was paid by someone else not connected to Know Labs, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Know Labs, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.